Conference
Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada
Abstract
The CheckMate-141 trial led to the approval of nivolumab in platinum-resistant metastatic/advanced squamous cell carcinomas of the head and neck (SCCHN). We evaluated the outcomes of SCCHN patients in Ontario, Canada, treated with nivolumab through retrospective review of the provincial treatment registry. Kaplan-Meier method was used to estimate overall survival (OS) and Cox regression to evaluate the prognostic effect of selected factors. …
Authors
Zereshkian A; Shafi R; Pond GR; Hotte SJ
Volume
47
Pagination
pp. 123-127
Publisher
Wolters Kluwer
Publication Date
May 2024
DOI
10.1097/cji.0000000000000501
Conference proceedings
Journal of Immunotherapy
Issue
4
ISSN
1524-9557